buparlisib

Buparlisib is an investigational drug that has been studied for its potential to treat various types of cancer. It is a small molecule inhibitor that targets the phosphatidylinositol 3-kinase (PI3K) pathway. The PI3K pathway is a crucial signaling cascade involved in cell growth, proliferation, and survival, and its dysregulation is frequently observed in many cancers. Buparlisib works by blocking the activity of certain PI3K enzymes, thereby aiming to inhibit cancer cell growth and induce cell death.

Clinical trials have explored buparlisib as a monotherapy and in combination with other anti-cancer agents for a range of malignancies, including breast cancer, glioblastoma, and certain hematological cancers. While some studies have shown promising activity, buparlisib has also been associated with specific side effects, such as hyperglycemia, rash, and mood changes, which are common with PI3K inhibitors. The drug's development has faced challenges, and its approval for widespread clinical use has not yet been achieved. Ongoing research continues to investigate its efficacy, safety profile, and potential role in personalized cancer treatment strategies.